Avelumab + enfortumab vedotin
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Penile Squamous Cell Carcinoma (PSCC)
Conditions
Penile Squamous Cell Carcinoma (PSCC)
Trial Timeline
Dec 16, 2025 → Nov 1, 2030
NCT ID
NCT07110038About Avelumab + enfortumab vedotin
Avelumab + enfortumab vedotin is a phase 2 stage product being developed by Astellas Pharma for Penile Squamous Cell Carcinoma (PSCC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07110038. Target conditions include Penile Squamous Cell Carcinoma (PSCC).
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07110038 | Phase 2 | Recruiting |
Competing Products
8 competing products in Penile Squamous Cell Carcinoma (PSCC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pembrolizumab + Standard of care therapy | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab | Roche | Phase 2 | 52 |
| Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires | Pfizer | Pre-clinical | 22 |
| Dacomitinib | Pfizer | Phase 2 | 51 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| Retifanlimab | Incyte | Phase 2 | 49 |